Nyxoah Appoints Rita Johnson-Mills to its board of directors
Mont-Saint-Guibert, Belgium – August 27, 2021, ten:30afternoon HEC / 4:30afternoon HEY – Nyxoah HER (Euronext Brussels / Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea (OSA), today announced that it has appointed Rita Johnson-Mills as as an independent director on its board of directors. administrators.
Robert Taub, Chairman of the Board of Directors of Nyxoah, said: “We are delighted to welcome Rita Johnson-Mills to the Board of Directors of Nyxoah. His wealth of knowledge, extensive operational experience and expertise in corporate governance will be invaluable as we navigate the healthcare industry with new and innovative solutions. The addition of Rita will also strengthen our presence in the United States and our commitment to board diversity.
Rita Johnson-Mills added, “Nyxoah is truly unique in the health technology arena and I am delighted to put my expertise to work for the board and the management team to identify ways to have a positive impact on the health and quality of life of those living with the debilitating impact. sleep breathing disorders.
Rita Johnson-Mills is a seasoned former healthcare executive. Rita’s background and experience includes 30 years of combined federal and state government and private industry experience, including 15 years directly responsible for the profitability and growth of healthcare organizations. She spent 11 years with UnitedHealthcare, most notably as CEO of UnitedHealthcare Community Plan of Tennessee. Rita currently serves on the board of directors of Brookdale Senior Living Inc. and Quest Analytics, LLC. Rita received a double master’s degree from Ohio State University, a master’s degree in public policy, and a master’s degree in labor / human resources. She is also a Certified Hogan Executive Coach and Fellow of the National Association of Corporate Directors.
The appointment of Rita Johnson-Mills takes effect immediately, subject to a final appointment by the next general meeting of shareholders.
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea (OSA). Nyxoah’s flagship solution is the Genio® System, a new generation CE validated patient-centered hypoglossal neurostimulation therapy for OSA, the world’s most common sleep respiratory disorder associated with increased risk of mortality. and co-morbidities, including cardiovascular disease, depression, and stroke. .
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE mark in 2019. The Company completed the BETTER SLEEP study in Australia and New Zealand for the extension of therapeutic indications and is currently conducting the pivotal DREAM IDE study for FDA approval and an EliSA post-marketing study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit http://www.nyxoah.com/.
To warn – CE marked since 2019. Experimental set-up in the United States. Limited by US federal law to experimental use in the United States.
Fabian Suarez, Chief Financial Officer
+32 (0) 10 22 24 55